Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2

Small trials have suggested that heterologous vaccination with first-dose ChAdOx1 and second-dose BNT162b2 may generate a better immune response than homologous vaccination with two doses of ChAdOx1. In this cohort analysis, we use linked data from Catalonia (Spain), where those aged

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature communications 2022-03, Vol.13 (1), p.1639-7, Article 1639
Hauptverfasser: Hermosilla, Eduardo, Coma, Ermengol, Xie, Junqing, Feng, Shuo, Cabezas, Carmen, Méndez-Boo, Leonardo, Fina, Francesc, Ballo, Elisabet, Martínez, Montserrat, Medina-Peralta, Manuel, Argimon, Josep Maria, Prieto-Alhambra, Daniel
Format: Artikel
Sprache:eng
Schlagworte:
631/326/590
631/326/596/4130
692/700/1538
692/700/478/174
Aged
BNT162 Vaccine - adverse effects
BNT162 Vaccine - therapeutic use
ChAdOx1 nCoV-19 - adverse effects
ChAdOx1 nCoV-19 - therapeutic use
Cohort analysis
Confidence intervals
Coronaviruses
COVID-19
COVID-19 - epidemiology
COVID-19 - prevention & control
COVID-19 vaccines
Homology
Humanities and Social Sciences
Humans
Immune response
multidisciplinary
Safety
SARS-CoV-2
Science
Science (multidisciplinary)
Severe acute respiratory syndrome coronavirus 2
Vaccination
Vaccination - adverse effects
Vaccination - methods
Vaccine efficacy
Vaccines
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Small trials have suggested that heterologous vaccination with first-dose ChAdOx1 and second-dose BNT162b2 may generate a better immune response than homologous vaccination with two doses of ChAdOx1. In this cohort analysis, we use linked data from Catalonia (Spain), where those aged
ISSN:2041-1723
2041-1723
DOI:10.1038/s41467-022-29301-9